EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Population Pharmacokinetics (PopPK) Support for Pediatric Dosing of Biological Products

Brianna Eales iD, Nada A Helal iD, Olivia Vattelana iD, Mohamad M Kronfol iD, Elimika Pfuma Fletcher iD, Yow-Ming Wang iD, Gilbert J Burckart iD, Jayabharathi Vaidyanathan iD, Shirley K Seo iD, Mohamed Ismail Nounou iD

The Journal of Clinical Pharmacology · 2024

DOI: 10.1002/jcph.6116 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Clinical Pharmacology, 2024. Verfasst von Brianna Eales und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, USA. Hauptthemen laut MEDLINE: Biological Products, United States Food and Drug Administration, Drug Labeling. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study assesses the use of population pharmacokinetics (PopPK) in supporting pediatric dosing of novel biological drug products. The labeling for biologic drug products approved by the US Food and Drug Administration (FDA) from 2002 until 2021 was reviewed to identify those with a pediatric indication. For the drugs with a pediatric indication, the dosing regimen(s) based on age groups, dosing strategy, the use of PopPK to support the dose, and the types of pediatric clinical trials were reviewed. Data were collected from FDA's review documents and product labels on the Drugs@FDA website, and as needed, more clinical trial details were collected from PubMed and clinicaltrials.gov. The role of PopPK analyses in dosing was captured when mentioned in the label or review as playing a role in selecting the approved pediatric dose and/or in verifying the adequacy of the studied dose to support labeling. Between 2002 and 2021, FDA approved 169 biological products, and 78 of 169 (46%) products have an approved indication for which the label contains dosing recommendations for pediatric use. For the 78 products approved in pediatrics, there was a total of 180 clinical trials that included pediatric patients. Phase 3 pediatric trials commonly supported pediatric approval and dosing for the reviewed products (64%, 50/78 products; 56.1%, 101/180 trials). PopPK analyses were reported to play a critical role in dose selection, prediction, and verification for 40 of the 78 products (51%), including informing pediatric dosing in the absence of pediatric data (e.g., drugs approved under animal rule), comparing exposures to the exposure range observed in adults, and informing alternative dosing strategies in certain age or body weight groups. PopPK analyses have been applied in a variety of ways to inform pediatric dosing and support extrapolation from adult data or other pediatric age groups for biologics. Understanding and learning from these past cases on the use of pharmacometrics tools to support pediatric dosing of biological products can inform future pediatric development programs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biological ProductsUnited States Food and Drug AdministrationDrug LabelingHumansChildUnited StatesChild, PreschoolInfantAdolescentModels, BiologicalDose-Response Relationship, DrugDrug ApprovalInfant, NewbornClinical Trials as TopicAge Factors

Stichwörter der Autor:innen

PopPK modeling/simulationbiological productsclinical trialspediatric dosingpopulation pharmacokinetics (PopPK)

Substanzen

Biological Products

Autor:innen und Institutionen

  • Department of Pharmacology and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, USA.
  • Irma Lerma Rangel School of Pharmacy, Texas A&M Health Science Center, Texas A&M University, College Station, TX, USA.
  • The University of Georgia College of Pharmacy , University of Georgia, Athens, GA, USA.
  • Office of Clinical Pharmacology (OCP), OTS | CDER | FDA, White Oak Campus, Silver Spring, MD, USA.

ORCID-Profile: Brianna Eales, Nada A Helal, Olivia Vattelana, Mohamad M Kronfol, Elimika Pfuma Fletcher, Yow-Ming Wang, Gilbert J Burckart, Jayabharathi Vaidyanathan, Shirley K Seo, Mohamed Ismail Nounou

Zitieren

APA

Eales, B., Helal, N. A., Vattelana, O., Kronfol, M. M., Fletcher, E. P., Wang, Y. M., Burckart, G. J., Vaidyanathan, J., Seo, S. K., & Nounou, M. I. (2024). Population Pharmacokinetics (PopPK) Support for Pediatric Dosing of Biological Products. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.6116

Vancouver

Eales B, Helal NA, Vattelana O, Kronfol MM, Fletcher EP, Wang YM, et al. Population Pharmacokinetics (PopPK) Support for Pediatric Dosing of Biological Products. The Journal of Clinical Pharmacology. 2024. doi:10.1002/jcph.6116

BibTeX
@article{Eales2024,
  author = {Eales, Brianna and Helal, Nada A and Vattelana, Olivia and Kronfol, Mohamad M and Fletcher, Elimika Pfuma and Wang, Yow-Ming and Burckart, Gilbert J and Vaidyanathan, Jayabharathi and Seo, Shirley K and Nounou, Mohamed Ismail},
  title = {Population Pharmacokinetics (PopPK) Support for Pediatric Dosing of Biological Products},
  journal = {The Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1002/jcph.6116}
}
Kostenlos starten →